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Protocol
Protocol for rapid assessment of the efficacy of
novel Wnt inhibitors using zebrafish models
Dysregulation of Wnt signaling is a hallmark of many cancers, and the development of effective,
non-toxic small-molecule Wnt inhibitors is desirable. Off-target toxicities of new compounds are
typically tested in mouse models, which is both costly and time consuming. Here, we present a
rapid and inexpensive protocol to determine the in vivo toxicity and efficacy of novel Wnt
inhibitors in zebrafish using a combination of a fluorescence reporter assay as well as eye rescue
and fin regeneration assays. These experiments are completed within 1 week to rapidly narrow
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SUMMARY
Dysregulation of Wnt signaling is a hallmark of many cancers, and the develop-
ment of effective, non-toxic small-molecule Wnt inhibitors is desirable. Off-
target toxicities of new compounds are typically tested in mouse models, which
is both costly and time consuming. Here, we present a rapid and inexpensive pro-
tocol to determine the in vivo toxicity and efficacy of novel Wnt inhibitors in ze-
brafish using a combination of a fluorescence reporter assay as well as eye rescue
and fin regeneration assays. These experiments are completed within 1 week to
rapidly narrow drug candidates before moving to more expensive pre-clinical
testing.
For complete details on the use and execution of this protocol, please refer to
Zhang et al. (2020).
BEFORE YOU BEGIN
Note: 6xTCF/LEF-miniP:dGFP zebrafish are a transgenic reporter zebrafish line that contains
six repeats of the TCF/LEF DNA binding site upstream of a minimal promoter, derived from
the PGL4 vector, and destabilized GFP (dGFP) sequence. In cells with activatedWnt signaling,
TCF/LEF transcription factors bind to the DNA binding site, leading to transcription of dGFP
and fluorescence in those cells (Shimizu et al, 2012). The zebrafish line is maintained by in-
crossing, and screening for GFP fluorescence in each generation is required.
Note: The syngeneic CG1 zebrafish line was used for the eye rescue experiment, however, any
strain can be used. A pigmented strain is ideal for easier visualization of eye formation.
Note: This protocol utilizes theWnt inhibitorN-((5-chloro-8-hydroxyquinolin-7-yl)(4-(diethyla-
mino)phenyl)-methyl)butyramide (CBA-1) (Zhang et al, 2020) but can be used to examine Wnt
inhibition and in vivo toxicity of any compound. Doses given to animals may need to be
adjusted based on potency and toxicity of compounds.
Note: A subset of the imaging for this protocol was done using the Vertebrate Automated
Screening Technology (VAST) Bioimager (Union Biometrica; Pardo-Martin et al., 2010;
Chang et al., 2012; Pulak, 2016). Using the VAST Bioimager allows for efficient high-
throughput larval imaging with automatic positioning of zebrafish larvae; however, imaging
may also be done on any fluorescence-equipped stereo microscope with a camera and im-
aging software.
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Note: All procedures described in this protocol have been approved by the University of Ken-
tucky’s Institutional Animal Care and Use Committee (protocol 2015-2225). All zebrafish ex-
periments that are performed following this protocol must be approved by the user’s Institu-
tional Animal Care and Use Committee. The eye regeneration assay may not require approval
at some universities, as the use of zebrafish <3 days post-fertilization (dpf) is not regulated un-
der current animal research guidelines.
KEY RESOURCES TABLE
MATERIALS AND EQUIPMENT
13 E3 Media – 20 mL 503 E3 Media in 980 mL H2O
Adjust the pH of 1xE3 media to 7.0 with NaHCO3 powder.
Tricaine-S Solution – 4 g Tricaine-S/1 L reverse osmosis (RO) H2O
Buffer solution to pH 7.0 using NaHCO3 powder.
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, peptides, and recombinant proteins
BIO Sigma-Aldrich B1686-5MG
CaCl VWR Cat #: 1B1110-500G
CBA-1 (biotinylated variant of N-((5-chloro-
8-hydroxyquinolin-7-yl)(4-(diethylamino)
phenyl)-methyl)butyramide)
Zhang et al 2020 N/A
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D2438-50ML
KCl VWR Cat #: 0395-500G
MgSO4 Sigma-Aldrich Cat #: 230391-500G
NaCl VWR Cat #: BDH9286-500G
Tricaine-S Pentair Aquatic TRS1
XAV939 Sigma-Aldrich X3004-5MG
Experimental models: Organisms/strains
CG1 zebrafish line Mizgireuv and Revskov, 2006 N/A
Tg(6xTCF/LEF-miniP:dGFP) transgenic
zebrafish line
Shimizu et al, 2012 N/A
Software and algorithms





Stereo dissection microscope Nikon SMZ 745
VAST BioImager Union Biometrica N/A
503 E3 Media
Reagent Final concentration Amount
NaCl 250 mM 14.6 g
KCl 8.5 mM 0.65 g
CaCl 16.5 mM 2.20 g
MgSO4 16.5 mM 4.05 g
Double-Distilled H2O n/a 1 L
Total n/a 1 L
ll
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Note: 503 E3 Media is suitable for use at 20C within 1 month. 13 E3 Media is suitable for
use at 20C within 2 weeks. Tricaine-S Solution is stored at 4C and suitable for use within
1 month.
Drug solutions: Drugs are prepared at a 10mM stock concentration by dissolving powder in an
appropriate volume of DMSO. From the stock, drugs are then dissolved in 1xE3 media or fish system
water to a final concentration of 1–10 mM (depending on the experiment being performed).
STEP-BY-STEP METHOD DETAILS
Wnt inhibitor drug screen in 6xTCF/LEF:GFP zebrafish
Timing: 5 days
Note: GFP signaling in 6xTCF/LEF-miniP:dGFP transgenic zebrafish is in response to induc-
tion of Wnt signaling during normal development. In this assay, chemical inhibition of the
Wnt pathway will lead to a decrease in GFP fluorescence, signifying a decrease in Wnt
pathway signaling.
Day 1
1. Prepare 1xE3 media and tricaine solution according to the materials table.
2. Set up an incross of 6xTCF/LEF-miniP:dGFP transgenic zebrafish for breeding. To do so, a 3:2 ra-
tio of females to males should be set up in a breeding tank with shallow water.
Note: A total of 12 embryos are used per drug treatment (1 row of a 96-well plate). For
example, with vehicle control, XAV939 and BIO controls, and one drug of interest, a total
of 48 GFP embryos will be required. Since not all embryos will be GFP-positive or survive,
aim to have >100 embryos to collect by setting up 4 mating tanks of zebrafish.
Day 2
3. Collect embryos in a 10 cm2 petri dish with approximately 25 mL of 1xE3 media and place in a
28C incubator overnight. Keep 30 embryos per petri dish.
Day 3
4. At 24 hpf, screen 6xTCF/LEF-miniP:dGFP transgenic zebrafish embryos for GFP fluorescence
using a fluorescence-equipped stereo microscope. Remove any embryos that are not
fluorescent.
Note:GFP fluorescence will present in a fan-like shape around the tail and bilateral sections in
the head at this timepoint in development (Figure 1A).
CRITICAL: It is important to choose embryos of similar fluorescence intensity and avoid
outliers. Select larvae with equal GFP expression to use for the drug screen. Remove
any larvae that are not fluorescent or have a different fluorescence intensity than the sur-
rounding larvae (Figure 1B). Approximately 60% of embryos collected will meet screening
criteria and can be used for drug screening.
5. Under a dissecting microscope, dechorionated screened larvae using ultra-fine point forceps to
gently pull apart the chorion and release the embryos.
ll
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Note: Dechorionation can also be performed using Pronase at a final concentration of 1 mg/
mL in 1xE3 media.
6. In a flat-bottom 96-well plate, add 1 dechorionated fish with 100 mL E3 media to each well.
a. Replace 1xE3 media in the plate of embryos with fresh 1xE3 media
b. Cut the tip off of a 200 mL pipette tip, just large enough for a 2 dpf zebrafish larva to fit through.
Using a P200 pipette, aspirate 100mL E3 media with one zebrafish larva from the plate and add
to an empty well.
7. Add 100 mL of 23 concentration of the desired drug (see note below) to each well, respectively.
Do the same dilution for DMSO/vehicle in E3 media as a control for normalization of fluorescent
signal intensity.
Note: For this protocol, 10 mM of the Wnt pathway inhibitor CBA-1 was used. 1 mM BIO, a
GSK3 inhibitor that activates Wnt pathway signaling, was used as a positive control (Sato
et al., 2004). 1 mM XAV939, a Tankyrase 1 inhibitor that inhibits Wnt pathway signaling, was
used as a negative control (Huang et al, 2009). DMSO was used as a vehicle control at a final
concentration of 0.1%.
Note: This addition of 100 mL of 23 drug + 100 mL E3 media will bring the final drug concen-
tration to 13. From the 10 mM stock solutions, CBA-1 and DMSO/vehicle control were diluted
1:500 in E3 media for the 23 concentration and BIO and XAV939 were diluted 1:5,000 in E3
media.
Figure 1. 6xTCF/LEF-miniP:dGFP Wnt inhibitor drug screen
(A) 6xTCF/LEF-miniP:dGFP zebrafish at 48 hpf; GFP fluorescence is an indicator of Wnt signaling during normal
development. There is extensive TCF/LEF-driven GFP expression in the head and tail regions (arrowheads). The yolk is
auto-fluorescent (*). The white box shows the tail area imaged for drug screen in (C-F).
(B) Screening of 6xTCF/LEF-miniP:dGFP zebrafish at 24 hpf. The chorion is circled to make visualization easier.
Embryos numbered 1-3 are examples of fish that have similar, bright fluorescence and would be selected for the drug
screen. Embryo 4 has no GFP fluorescence, while embryo 5 has very dim fluorescence; both should be excluded from
the screen.
(C) DMSO (vehicle) control fish showing normal pattern of GFP expression in the tail.
(D) Treatment with the Wnt pathway activator BIO leads to an increase in GFP fluorescence in the tail.
(E) Treatment with the Wnt inhibitor XAV939 leads to a decrease or complete loss of GFP fluorescence in the tail.
(F) Treatment with a less potent Wnt pathway inhibitor, CBA-1, leads to a decrease but not complete loss of GFP
fluorescence. Images (C-F) were taken at 72 hpf. Scale bar = 500 mm
ll
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8. Place the plate into a 28C incubator and leave for 48 h of drug treatment.
Note: If the drug of choice is light-sensitive, incubation can be done in the dark (either in an
incubator in a dark room or by covering the plates with aluminum foil).
Day 4
9. Examine the larvae daily and remove any larvae that are dead or developmentally abnormal. The
drug may be too toxic if there are a large number of dead or deformed larvae. Record the number
of dead/deformed larvae for toxicity purposes.
Note: If 10 mM of the drug of choice is too toxic for zebrafish larvae or no effect is seen at this
dose, the maximum tolerated dose for your drug of choice should be determined and used for
the drug screen (see Troubleshooting Problem 2 below).
Day 5
10. After 2 days of drug treatment, image 72 hpf larvae on the VAST Bioimager at 488 nm excitation/
509 nm emission to visualize GFP (Union Biometrica; Pardo-Martin et al., 2010; Chang et al.,
2012; Pulak, 2016). Image only the tails of the 6xTCF/LEF-miniP:dGFP larval fish just above
the anal canal and avoid imaging yolk. The autofluorescence of the yolk can interfere with down-
stream quantification. Using the tail only for GFP-quantification yields the most reproducible re-
sults (Figures 1C–1F).
a. Start with DMSO control fish to set the exposure level before moving on to positive and
negative controls and then the drug(s) of choice.
b. Maintain constant exposure settings throughout all images.
Note: The VAST bioimager automatically adds Tricaine-S solution to wells of 96-well plate to
anesthetize animals for imaging. If not using VAST bioimager, fish can be anesthetized in a
final concentration of 50–100 mg/L of Tricaine-S before imaging.
Pause point: Once images have been taken, quantification can be done at any point.
11. Quantify fluorescence using FIJI Image J software and macro as previously described in Haney
et al. 2020.
a. Multiply (mean fluorescence intensity) 3 (area of fluorescence) for each image.
b. Normalize values to vehicle control (DMSO in this experiment) by dividing the above number
by the average (mean 3 area) for all DMSO fish.
Caudal fin regeneration assay in wild-type fish
Timing: 5 days
Note: Zebrafish caudal fins will regenerate if they are cut immediately rostral to the bifurcation
of the caudal fin (Figure 2A). This regeneration is dependent on Wnt pathway signaling (Sto-
ick-Cooper et al, 2007). Chemical inhibition of Wnt signaling will lead to reduced caudal fin
regeneration, signifying a decrease in Wnt pathway signaling.
Note: For this assay you will need 6 adult wild-type zebrafish (of any sex) per drug treatment.
For example, if using DMSO/vehicle control, XAV939 control, and a potential Wnt
inhibitor compound, a total of 18 adult zebrafish would be required for this experiment.
This number was chosen as a pilot study to not overcrowd tanks and not require too much
ll
OPEN ACCESS
STAR Protocols 2, 100433, June 18, 2021 5
Protocol
drug. Power analysis can be done based of this study to decide howmany fish are required for
further studies.
Day 1
12. Anesthetize adult (3–12 months of age) wild-type fish by placing the fish in a 10 cm2 petri dish
containing 25 mL of fish system water with 100 mL of 4mg/mL Tricaine-S solution for approxi-
mately 1–2 min.
13. Remove the fish from the Tricaine-water and place on a clean 10 cm2 petri dish. Using a
razor blade, cut off the end of the fish’s tail just rostral to the bifurcation of the caudal fin (Fig-
ure 2A).
CRITICAL: Do not cut the tail fin too close to the musculature in the tail (Figure 2A). Larger
wounds have more blood loss and risk of infection, increasing the likelihood of mortality.
14. Immediately place fish into a large (4L) tank with fish system water to recover for 20 min.
a. Repeat steps 8 and 9 for enough fish for n=6/drug treatment group.
15. After the recovery period, place amputated fish (n=6/group) in a small tank, such as a small
breeding tank (18 cm 3 8 cm 3 7 cm), with 250 mL of fish system water (approximately
2.5 cm depth) containing 5 mM of Wnt inhibitor compound to be tested, DMSO (or the corre-
spondent vehicle) as a negative control, or 1 mM of XAV939 as a positive control.
Note: 5 mM drug concentration was chosen for this assay due to the larger amount of drug
stock required to perform this assay on adult zebrafish.
16. Leave the tank of drug-treated, amputated fish at ambient temperature (approximately 28C).
Do not feed the fish until immediately prior to water changes to keep the tank clean.
Day 2 (1 day post-amputation)
17. Move fish to a new tank with 250 mL of fresh fish system water containing the fresh drug.
Day 3 (2 days post-amputation)
18. Feed fish with dry food, wait 15 min for the fish to eat, and then move fish to a new tank with
250 mL of fresh fish system water containing the fresh drug.
Figure 2. Caudal fin regeneration assay
(A) Caudal fins are amputated with a razor blade immediately rostral to the fin bifurcation. Cuts made too close to the
tail musculature (arrowhead) will likely result in zebrafish mortality.
(B) DMSO control treated zebrafish show regeneration of the caudal fin 4 days post-amputation, with the amount of
growth measured (red line).
(C) Wnt inhibitor (XAV939) treated caudal fins fail to regenerate. Scale bar = 2 mm.
ll
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Day 4 (3 days post-amputation)
19. Move fish to a new tank with 250 mL of fresh fish system water containing the fresh drug.
Day 5 (4 days post-amputation)
20. Image fish at 4 days post-amputation using any stereo microscope. Take images of the tail
regeneration front (Figure 2B and C). Fish can be anesthetized with a final concentration of
50–100 mg/L or euthanized with >400 mg/L Tricaine-S for ease of imaging.
21. Using the measurement feature in FIJI Image J software, measure the length of growth of each
tail from the cut point to the farthest point of growth (Figures 2B and 2C).
Note: Fish may be fixed in 4% paraformaldehyde in PBS overnight at 4C then moved to PBS
and held in a 4C refrigerator for imaging within one week.
Eye rescue in wild-type fish
Timing: 4 days
Note: Zebrafish eye development is dependent on a proper balance of Wnt pathway
signaling. When the balance of Wnt/Beta-catenin signaling is altered towards increased
Wnt signaling during early development, zebrafish will develop an eyeless phenotype (van
de Water et al, 2001). In this assay, over-stimulation of Wnt pathway signaling is achieved
by treating zebrafish embryos during the first 6 h of development with the compound BIO.
The resulting eyeless phenotype can then be rescued by reducing Wnt pathway signaling
via treatment with a Wnt pathway inhibitor compound.
Note: This experiment requires 30 embryos per drug treatment for a pilot study. For this
experiment, with BIO and DMSO/vehicle control, XAV939 and a Wnt inhibitor, a total of
120 embryos are required. This pilot experiment can then be repeated with 3 independent
replicates and the results between trials averaged to increase statistical power.
Day 1
22. Set up an incross of any pigmented wild-type zebrafish line for breeding. To do so, place a
divider in a breeding tank with shallow water. A 3:2 ratio of females to males should be set
up, using the divider to separate males and females.
Day 2
23. In the early morning, remove the divider from the breeding tank(s) to allow the zebrafish to
begin breeding. Check for embryos every 15 min after removing the divider and collect any em-
bryos that have been laid, recording the time of collection as time gates were pulled. This can be
repeated, checking for new eggs laid and collecting them every 15 min until enough eggs are
collected to perform the experiment.
24. Collect embryos in a 10 cm2 petri dish in 1xE3 media and place in a 28C incubator until ready to
use. Embryos will be used for drug-treatment at 6 hpf.
25. In a 6-well plate, add 1 mM BIO + 10 mMCBA-1, or experimental drug of interest, in 9 mL E3 me-
dia per well.
a. Use vehicle/DMSO, BIO treatment alone, and BIO plus 10 mM XAV as controls.
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Note:When transferring embryos to the drug-treatment wells from the 10 cm2 petri dish they
were collected into, make sure to add as little E3 media with the embryos as possible. This
ensures the drug concentration remains at the desired concentration. Hold the transfer
pipette vertically and allow embryos to settle to the bottom of the transfer pipette before
expelling fish to avoid transferring large volumes of liquid.
CRITICAL: Make sure fish are set up to breed with gates in place and keep track of the time
the fish lay embryos. The addition of drug at the shield stage of development (at 6 hpf) is
critical for viable embryo development and the eyeless phenotype.
27. Place embryos in drug treatment in a 28C incubator.
Day 4
28. Using a stereo microscope, count the number of eyes present in fish at 48 hpf (Figures 3A–3D).
Record the number of fish with no eyes, one eye, or two eyes.
Note: Eye development can be assessed at 24 or 48 hpf depending on toxicity of the drugs
being used. The phenotype will not change after 24 hpf, however the eyes will be larger
and more pigmented at 48 hpf and are easier for counting and imaging.
Note: Treatment with BIO is toxic to zebrafish embryos during development as it interferes
with normal early development pathway signaling. Phenotypes such as pericardial enlarge-
ment, pink coloration in the yolk, and tail atrophy or curvaturemay be seen. These phenotypes
will not affect the eye rescue phenotype outcomes.
Note: A dose response curve can be done to determine strength of Wnt pathway inhibition.
This is done by treating groups of embryos with 1, 2, 5, and 10 mM of the drug of interest plus
1 mM BIO in the same manner as described above. Results should indicate an increase in the
number of two-eyed embryos, a decrease to almost no one-eyed embryos, and a lack of no
eyed embryos as the dose increases.
Figure 3. Eye rescue assay
(A) Treatment with BIO leads to overactivation of Wnt signaling and a loss of eye development, as well as other
developmental abnormalities.
(B) Simultaneous addition of a Wnt inhibitor (XAV939) along with BIO treatment rescues the eyeless phenotype.
(C and D) show the boxed head regions from A and B, respectively. Scale bar in A and B = 500 mm. Scale bar in C and
D = 250 mm.
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EXPECTED OUTCOMES
For the drug screen in 6xTCF/LEF-miniP:dGFP transgenic animals, any drugs that inhibit Wnt
pathway signaling should lead to a decrease in GFP fluorescence in the tail region. For very good
inhibitors, a complete loss of GFP fluorescence may be seen in the tail region after 48 h of drug treat-
ment (72 hpf). For the controls, BIO treatment will cause an increase in GFP expression and XAV939
will cause almost a complete loss of GFP expression (Figure 1D and E). For less strong Wnt pathway
inhibitors, there will be a decrease in GFP expression that can be seen and quantified, but not a com-
plete loss of GFP signal (Figure 1F).
For the caudal fin regeneration assay, zebrafish caudal fins will regenerate if they are cut just rostral
to the bifurcation of the fin. This regeneration is dependent on Wnt signaling. In this experiment,
DMSO serves as the vehicle control and XAV939, a known Wnt pathway inhibitor, serves as the pos-
itive control. The fish in the DMSO/vehicle control group will have normal Wnt pathway signaling,
and will have measurable tail fin regeneration after 4 days at the site of amputation (Figure 2B). In-
hibition of Wnt signaling with XAV939 will lead to no tail fin re-growth where the fin was cut (Fig-
ure 2C). The effects of the small molecule being tested should be compared to those of the
DMSO/vehicle control group and the XAV939 positive control group. If the small molecule being
tested is a strong inhibitor of Wnt signaling, regrowth of the tail fin will be significantly reduced
compared to DMSO.
Normal development of the zebrafish embryo is dependent on the correct balance of Wnt pathway
signaling. Eye development is especially sensitive to disruptions in timing of Wnt signaling events.
Addition of BIO to embryos at 6 hpf (shield stage) activates Wnt signaling and results in a failure of
eye development (Figures 3A and 3C). However, when embryos are concurrently treated with BIO
and aWnt inhibitor, the balance ofWnt pathway signaling will be restored and the loss of eye pheno-
type is reversed (Figures 3B and 3D).
LIMITATIONS
There is an inherent degree of variation that should be expected in animal studies. A large enough
sample size needs to be used to ensure enough statistical power to see differences in GFP expres-
sion, fin regeneration, and eye development. Drug concentrations and numbers of animals used
may need to be optimized based on the properties of the drug and how well the imaging set-up
used can distinguish changes in GFP fluorescence. Another potential limitation is that the drug
needs to be soluble in water and stable enough to be absorbed from the water into the zebrafish
larvae over the treatment period without breaking down. Additionally, although rare, some com-
pounds may be toxic to zebrafish larvae but not in mammals, so false positives for toxicity may be
observed. The opposite may also be true, with some drugs being toxic in mammals but not in the
zebrafish, resulting in false positives for drug efficacy.
TROUBLESHOOTING
Problem 1
The drug of interest precipitates in water (protocol steps 7, 15, and 25)
Potential solution
Check the drug properties tomake sure that the drug is soluble in water or at least will not precipitate
out at the desired concentration. A lower concentration can be tried to see if the drug still precipi-
tates out. However, some drugs will continue to precipitate and cannot be used for zebrafish assays
in vivo as the zebrafish larvae may consume the drug precipitates.
Problem 2
The drug of choice is too toxic and kills the fish at the suggested concentration, or there is no effect
seen with the dose of the drug chosen (protocol step 9).
ll
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Potential solution
A maximum tolerated dose (MTD) assay (Hutchinson et al, 2009; Maes et al, 2012) can be done to
determine what the MTD is for your drug of choice in zebrafish. This is done by testing a broad range
of doses in zebrafish larvae at the same age that would be done in the experiment, and quantifying
signs of obvious toxicity or animal death. The highest dose that is tolerated without causing toxicity
or death should be used for animal studies. This dose may be different in larval and adult fish.
Problem 3
In the TCF/LEF larval drug screen, the entire fish appears fluorescent in the GFP channel when
treated with the Wnt inhibitor of choice (protocol step 10).
Potential solution
Some drugs have auto-fluorescent or fluorescent properties in the GFP channel. Check to make sure
the drug of choice does not fluoresce in the GFP channel. If so, this assay cannot be performed with
this drug; however the other two assays can still be done to assess Wnt inhibition in vivo.
Problem 4
When performing the tail regeneration experiment, the tail fails to grow back in the DMSO/vehicle
control group (protocol step 13).
Potential solution
It is likely that the cut made in the tail was too far rostral in the tail and into the tail musculature. Re-
view Figure 2A for a clear view of the optimal cutting location.
Problem 5
When performing the eye rescue experiment, the eyes fail to disappear with BIO treatment (protocol
step 26).
Potential solution
It is likely that the BIO was not added at the correct timepoint before eye development began. Begin
timing immediately after gates are pulled, restarting the timer and collecting embryos every 15 min,
so that BIO is added during the shield stage of development (6 hpf). Embryos should also be kept at
28C so that the speed of development is not changed due to a non-physiologic temperature.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Jessica Blackburn at jsblackburn@uky.edu.
Materials availability
Zebrafish lines used in this study are available via the Zebrafish International Research Center (ZIRC)
and can be made available by request. Plasmids used to create zebrafish lines or zebrafish them-
selves can also be shipped upon request to the lead contact.
Data and code availability
This study did not generate/analyze any datasets or code.
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C., and Yanik, M.F. (2012). Fully automated cellular-
resolution vertebrate screening platform with
parallel animal processing. Lab Chip 12, 711–716.
Haney, M.G., Moore, H., and Blackburn, J.S. (2020).
Drug screening of primary patient derived tumor
xenografts in zebrafish. J. Vis. Exp. 158.
Huang, S.A., Mishina, Y.M., Liu, S., Cheung, A.,
Stegmeier, F., Michaud, G.A., Charlat, O.,
Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009).
Tankyrase inhibition stabilizes axin and
antagonizes Wnt signaling. Nature 461, 614–620.
Hutchinson, T.H., Bogi, C., Winter, M.J., and
Owens, J.W. (2009). Benefits of the maximum
tolerated dose (MTD) and maximum tolerated
concentration (MTC) concept in aquatic toxicology.
Aquat. Toxicol. 91, 197–202.
Maes, J., Verlooy, L., Buenafe, O.E., de Witte,
P.A.M., and Esguerra, C.V. (2012). Evaluation of 14
Organic solvents and carriers for screening
applications in zebrafish embryos and larvae. PLoS
One 7, e43850.
Mizgireuv, I.V., and Revskoy, S.Y. (2006).
Transplantable tumor lines generated in clonal
zebrafish. Cancer Res, 66, 3120–3125.
Pardo-Martin, C., Chang, T.-Y., Koo, B.K., Gilleland,
C.L., Wasserman, S.C., and Yanik, M.F. (2010).
High-throughput in vivo vertebrate screening. Nat.
Methods 7, 634–636.
Pulak, R. (2016). Tools for automating the imaging
of zebrafish larvae. Methods 96, 118–126.
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P.,
and Brivanlou, A.H. (2004). Maintenance of
pluripotency in human and mouse embryonic stem
cells through activation of Wnt signaling by a
pharmacological GSK-3-specific inhibitor. Nat.
Med. 10, 55–63.
Shimizu, N., Kawakami, K., and Ishitani, T. (2012).
Visualization and exploration of Tcf/Lef
function using a highly responsive Wnt/b-catenin
signaling-reporter transgenic zebrafish. Dev. Biol.
370, 71–85.
Stoick-Cooper, C.L., Weidinger, G., Riehle, K.J.,
Hubbert, C., Major, M.B., Fausto, N., and Moon,
R.T. (2007). Distinct Wnt signaling pathways have
opposing roles in appendage regeneration.
Development 134, 479–489.
Van de Water, S., van de Wetering, M., Joore, J.,
Esseling, J., Bink, R., Clevers, H., and Zivkovic, D.
(2001). Ectopic Wnt signal determines the eyeless
phenotype of zebrafish masterblind mutant.
Development 128, 3877–3888.
Zhang, W., Sviripa, V.M., Xie, Y., Yu, T., Haney,
M.G., Blackburn, J.S., Adeniran, C.A., Zhan, C.,
Watt, D.S., and Liu, C. (2020). Epigenetic
regulation of Wnt signaling by carboxamide-
substituted benzhydryl amines that function as




STAR Protocols 2, 100433, June 18, 2021 11
Protocol
